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Background: Dominant mutations in superoxide dismutase 1 (SOD1) cause degeneration of motor neurons in a subset
of inherited amyotrophic lateral sclerosis (ALS). The pathogenetic process mediated by misfolded and/or aggregated
mutant SOD1 polypeptides is hypothesized to be suppressed by protein refolding. This genetic study is aimed to test
whether mutant SOD1-mediated ALS pathology recapitulated in mice could be alleviated by overexpressing a
longevity-related deacetylase SIRT1 whose substrates include a transcription factor heat shock factor 1 (HSF1), the
master regulator of the chaperone system.
Results: We established a line of transgenic mice that chronically overexpress SIRT1 in the brain and spinal cord. While
inducible HSP70 (HSP70i) was upregulated in the spinal cord of SIRT1 transgenic mice (PrP-Sirt1), no neurological and
behavioral alterations were detected. To test hypothetical benefits of SIRT1 overexpression, we crossbred PrP-Sirt1 mice
with two lines of ALS model mice: A high expression line that exhibits a severe phenotype (SOD1G93A-H) or a low
expression line with a milder phenotype (SOD1G93A-L). The Sirt1 transgene conferred longer lifespan without altering
the time of symptomatic onset in SOD1G93A-L. Biochemical analysis of the spinal cord revealed that SIRT1 induced
HSP70i expression through deacetylation of HSF1 and that SOD1G93A-L/PrP-Sirt1 double transgenic mice contained less
insoluble SOD1 than SOD1G93A-L mice. Parallel experiments showed that Sirt1 transgene could not rescue a more severe
phenotype of SOD1G93A-H transgenic mice partly because their HSP70i level had peaked out.
Conclusions: The genetic supplementation of SIRT1 can ameliorate a mutant SOD1-linked ALS mouse model partly
through the activation of the HSF1/HSP70i chaperone system. Future studies shall include testing potential benefits of
pharmacological enhancement of the deacetylation activity of SIRT1 after the onset of the symptom.
Keywords: Sirtuin 1 (SIRT1), Cu/Zn-superoxide dismutase (SOD1), Heat shock factor 1 (HSF1), Heat shock protein (HSP),
Amyotrophic lateral sclerosis (ALS), Systematic behavioral screening* Correspondence: kinoshita.makoto@c.mbox.nagoya-u.ac.jp;
kojiyama@riem.nagoya-u.ac.jp
†Equal contributors
2Department of Molecular Biology, Division of Biological Sciences, Nagoya
University Graduate School of Science, Furo-cho, Chikusa, Nagoya 464-8602,
Japan
1Department of Neuroscience and Pathobiology, Research Institute of
Environmental Medicine, Nagoya University, Furo-cho, Chikus, Nagoya
464-8601, Japan
Full list of author information is available at the end of the article
© 2014 Watanabe et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Watanabe et al. Molecular Brain 2014, 7:62 Page 2 of 11
http://www.molecularbrain.com/content/7/1/62Background
Pathological protein aggregation is a major hallmark of
neurodegenerative diseases including amyotrophic lateral
sclerosis (ALS), Parkinson’s disease, Alzheimer’s disease and
polyglutamine diseases [1]. In ALS, approximately 10% is
inherited and about 20% of the inherited ALS are caused by
dominant mutations in the gene encoding Cu/Zn-super-
oxide dismutase (SOD1) [2]. Many of ALS causative SOD1
mutants retain the enzymatic activity for catalyzing super-
oxide anion to hydrogen peroxide and deletion of wild-type
SOD1 from mice does not cause ALS phenotype, suggest-
ing that SOD1 mutants provoke motor neuron degener-
ation through “gain of toxic function” mechanisms [3]. It
has been suggested that altered conformations of mutant
SOD1 proteins are linked to the toxicity [4]. Recent studies
demonstrated that accumulation of misfolded SOD1 pro-
teins is not only specific to SOD1-related familial ALS but
also involved in a subset of sporadic ALS [5,6].
Chaperone system is a major cytoprotective mechanism
against proteotoxic stresses. Unfolded or misfolded pro-
teins are restored to their proper conformations with the
help of heat shock proteins (HSPs) including HSP110/
105, constitutive and inducible HSP70s (HSC70, HSP70i).
HSP110/105, HSP70i, and HSP40 directly bind to mutant
SOD1 and facilitate the clearance of SOD1 through the
ubiquitin-proteasome pathway [7–9], suggesting that HSPs
are involved in the neuroprotective mechanisms against
SOD1-mediated neurodegeneration. Indeed, HSP70i co-
expression in motor neurons substantially inhibits the
SOD1-aggregation and improves the cell viability [10].
Moreover, HSP70i is also effective against other neuro-
degenerative diseases, such as Parkinson’s disease [11]
and Alzheimer’s disease [12]. These data suggest that the
induction of HSPs is a promising therapeutic strategy for
neurodegenerative diseases including ALS.
Upon exposure to proteotoxic stresses, heat shock
factor 1 (HSF1) forms a trimer, translocates to the nu-
cleus, binds to regulatory elements of DNA, and upre-
gulates a set of genes including HSP70i whose products
constitute the chaperone system [13]. Deacetylation of
HSF1, which is mediated partly by a sirtuin family dea-
cetylase SIRT1, prolongs its binding to the heat shock
promoters [14]. Recent studies have demonstrated benefi-
cial effects of resveratrol, which is considered to potentiate
the sirtuin cascade, on SOD1-ALS models [15,16]. Given
the pleiotropic effect of resveratrol through non-sirtuin
targets, the role of SIRT1 in motor neuron degeneration is
to be examined. However, the effect of genetic supple-
mentation of SIRT1 in ALS mice has never been directly
tested.
On the basis of the above background, in this study we
establish transgenic mouse lines that express SIRT1 in the
central nervous system (CNS) under control of the murine
prion promoter (PrP). We find that modest overexpressionof SIRT1 alone does not cause neurological and behavioral
alterations. To test the effects of SIRT1 overexpression, we
crossbred the line with either of the two lines of transgenic
mice which express a high and a low dose of the toxic
SOD1G93A polypeptide that recapitulate selective motor
neuron degeneration. We find that SIRT1 overexpression
consistently endows partial rescue effects with the milder
ALS model with the lower dose of SOD1G93A. Biochemical
analysis of the spinal cord extracts reveals upregulation of
HSP70i and reduced aggregation of SOD1G93A in the
SOD1G93A/PrP-Sirt1 mice, corroborating the beneficial
role of SIRT1 partly through activating the HSF1/HSP70i
system.Results
Generation of a prion promoter-driven Sirt1 transgenic mouse
We generated transgenic mice that chronically express
mouse SIRT1 in the CNS under control of the murine
prion gene promoter (Figure 1A) (see Methods). The
founder transgenic mice were backcrossed with wild-type
C57BL/6 J mice, and a transgenic line with the highest
SIRT1 protein level in the brain was selected. The off-
spring was further backcrossed for more than ten genera-
tions and established a transgenic line that gave consistent
pan-neural expression of exogenous SIRT1. We compared
the heterozygous Sirt1 transgenic mice (PrP-Sirt1) with
their non-transgenic littermates for the expression level of
SIRT1 protein in the brain and spinal cord. Immunoblot
analyses for SIRT1 confirmed the clear induction of ac-
tive SIRT1 in the brain and spinal cord of PrP-Sirt1 mice
(Figure 1B) (Additional file 1: Figure S1). In the PrP-Sirt1
mouse spinal cord, the expression level of SIRT1 protein
was about three-fold higher than the one in the non-
transgenic littermates. The lifespan of the PrP-Sirt1 mice
was comparable to that of their non-transgenic littermates
(Figure 1C).Chronic overexpression of SIRT1 in the CNS does not
affect the behavior of mice
As a means of unbiased screening for potential neuro-
logical alterations, PrP-Sirt1 mice were subjected to a
battery of physical and behavioral examinations. Over-
all, PrP-Sirt1 transgenic and non-transgenic male lit-
termates (n = 15 and 20, tested at 5–9 months of age)
did not differ in their physical and behavioral indices
quantified, except for a few minor items (Table 1 and
Additional file 1: Figure S3-S17. The raw data are accessible
at the Mouse Phenotype Database, http://www.mouse-
phenotype.org/). These findings indicate that chronic
overexpression of SIRT1 in the mouse CNS does not
cause major physical or neuropsychiatric alterations up
to that age.
Figure 1 Generation of a line of transgenic mice that overexpress SIRT1 (PrP-Sirt1). (A) Schematic diagram of transgenes used to generate
PrP-Sirt1 founder mice. Full-length mouse Sirt1 cDNA was subcloned into the MoPrP (mouse prion promoter)-vector [37]. The non-coding portion
of exon 2 and 3, and the Sirt1 cDNA insert (with its own start and stop codon) were fused into one exon. The linearized transcription unit was
co-injected with a visual marker, α-crystallin promoter-driven enhanced green fluorescent protein (EGFP) cDNA. (B) SIRT1 expression in PrP-Sirt1
and non-transgenic (nTg) mouse spinal cord. The expression level of Sirt1 was quantified in three independent experiments and shown as
mean ± standard error of the mean (SEM). The data was analyzed by Student’s t-test. (C) Survival curve of the PrP-Sirt1 and nTg mice plotted over
time (n = 28 each). Mean survival time (days) was shown with standard deviation (SD).
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SOD1G93A and SOD1G37R transgenic mouse
We have previously reported that HSP70i is induced in
the spinal cord of SOD1G93A transgenic mouse [9]. To
test the possible involvement of SIRT1 in the induction
of HSP70i, we investigated the expression level of SIRT1
in the spinal cords of high expression line of SOD1G93A
mouse (SOD1G93A-H) and SOD1G37R transgenic mouse
which expresses human SOD1 gene carrying another
ALS-linked mutation [17,18]. SIRT1 and HSP70i were
clearly upregulated toward the end stage (5 months of
age) of SOD1G93A-H mice (Figure 2A). In SOD1G93A-H/
PrP-Sirt1 double transgenic mice, the level of HSP70i was
not different from that of SOD1G93A-H mice (Figure 2A)
(Additional file 1: Figure S1), suggesting that the induc-
tion of HSP70i had peaked out. Similarly, SIRT1 was up-
regulated from around the symptomatic onset (10 months
of age) to the end stage (13 months of age) in the spinal
cords of SOD1G37R mice (Figure 2B). HSP70i was in-
duced only at the end stage, when HSP90 and HSP110/
105 were downregulated (Figure 2C), consistent with
our previous results on the expression of HSPs in
SOD1G93A mice [9].SIRT1 overexpression extends lifespan of the transgenic
mouse expressing low copy of SOD1G93A
To examine putative beneficial effects of SIRT1 overex-
pression on the neurotoxicity by mutant SOD1, we cross-
bred the PrP-Sirt1 mice with two lines of SOD1G93A
transgenic mice; SOD1G93A-H and SOD1G93A-L with a
lower copy number . SOD1G93A-L mice express SOD1G93A
transgene approximately 60% of SOD1G93A-H mice
(Additional file 1: Figure S2) and survive about 30 days
longer on average (Figure 3A). We found that SIRT1
overexpression significantly extended the lifespan of
SOD1G93A-L mice (Figure 3A) without altering the on-
set of disease (Figure 3B). In contrast, SIRT1 did not
give any beneficial effects on the lifespan (Figure 3C)
and the disease onset of SOD1G93A-H mice (Figure 3D).
The disease progression was analyzed by dividing the
total disease duration into the early and late phases
(Figure 4A). SIRT1 extended the total disease duration
in SOD1G93A-L mice (74.6 ± 18.8 days for SOD1G93A-L/
PrP-Sirt1; 63.2 ± 12.6 days for SOD1G93A-L) (Figure 4B).
Interestingly, while the early phase duration was slightly
reduced (34.3 ± 9.32 days for SOD1G93A-L/PrP-Sirt1;
42.0 ± 10.3 days for SOD1G93A-L) (Figure 4C), further
Table 1 Summary of systematic behavioral tests for PrP-Sirt1 mice in comparison with wild-type littermates
Tests Mental/physical activities Indices measured Alteration from wild
type
(inexhaustive) PrP-Sirt1
General health and neurological
screening
General health Body weight ↓
(Additional file 1: Figure S3) Rectal temperature →
Grip strength →
Hanging persistence ↓
Light/dark transition test Exploratory activity Distance traveled in the light chamber →
(Additional file 1: Figure S4) Light avoidance Distance traveled in the dark chamber →
Latency to the first entry to the light
chamber
→
Time stayed in the light chamber →
Number of transitions between chambers ↓
Open field test Exploratory activity Distance traveled ↑
(Additional file 1: Figure S5) Avoidance from open space Center time →
Anxiety-like behavior Vertical activity →
Stereotypic counts →
Elevated plus maze test Exploratory activity Distance traveled →
(Additional file 1: Figure S6) Height avoidance Entries into open arms →
Number of entries →
Time stayed on open arms →
Acoustic startle response Startle reflex to loudness Ampliture of body motion →
(Additional file 1: Figure S7A)
Prepulse inhibition (PPI) test Sensorimotor gating Decrement of startle amplitude →
(Additional file 1: Figure S7B)
Porsolt forced swim test Despair-like behavior Latency to immobility →
(Additional file 1: Figure S8)
Home cage monitoring Diurnal cycle of locomotor activity Activity level (distance traveled) →
(Additional file 1: Figure S9) Social behavior Mean number of particles →
Social interaction test Social behavior, anxiety-like
behavior
Distance traveled →
(1 chamber, stranger pair) Number of contacts →
(Additional file 1: Figure S10) Total duration of active contacts →
Mean contact duration →
Total duration of contacts →
Social interaction test Social behavior, anxiety-like
behavior
Time spent with novel stranger ↓ (Step 2)
(3 chamber, 1–2 caged strangers)
(Additional file 1: Figure S11) Distance traveled →
Rota-rod test Motor coordination/learning Latency to fall →
(Additional file 1: Figure S12)
Gait analysis Mechanics of limb movement Limb positions and timings → (front step angle)
(Additional file 1: Figure S13) ↑ (hind step angle)
Hot plate test Aversive response to noxious
stimulus
Latency to limb withdrawal →
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Table 1 Summary of systematic behavioral tests for PrP-Sirt1 mice in comparison with wild-type littermates (Continued)
(Additional file 1: Figure S14)
Tail suspension test Behavioral despair Latency to immobility →
(Additional file 1: Figure S15)
Barnes maze Spatial memory Time spent around each hole →
(Additional file 1: Figure S16)
Fear conditioning test Fear memory Conditioning →
(Additional file 1: Figure S17) Contextual testing →
Cued test with altered context →
Comparative table of behavioral test results with PrP-Sirt1 and wild-type littermate C57BL/6 J mice. Symbols: →, no significant difference; ↑↓, statistically significant
increase and decrease as compared with wild-type control mice. N.D., not determined.
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20.2 days for SOD1G93A-L/PrP-Sirt1; 21.2 ± 8.92 days
for SOD1G93A-L) (Figure 4D). These data indicate that
SIRT1 overexpression was sufficient to slow the disease
progression of SOD1G93A-L mice, but not of SOD1G93A-
H mice.
SIRT1 overexpression causes deacetylation of HSF1,
upregulation of HSP70i, and reduction of misfolded
SOD1G93A
To assess whether the disease progression is correlated
with the deactylation level of HSF1 and/or the expres-
sion of HSP70i, we performed immunoprecipitation and
immunoblot analysis. In a 5-month-old PrP-Sirt1 mouse
spinal cord, the ratio of acetylated HSF1 over total HSF1
was significantly less and the level of HSP70i was signifi-
cantly higher than those of the littermate (Figure 5A and
B). These data suggest direct or indirect activation of the
HSF1/HSP70i pathway by SIRT1 overexpression. Despite
SIRT1 overexpression, however, HSP70i was not further
upregulated in SOD1G93A-H, SOD1G93A-L mice at the
end stage (Additional file 1: Figure S1), implying that
HSP70i had been peaked out. To test the putative bene-
ficial effects of SIRT1 overexpression against SOD1G93A-
mediated proteotoxicity, we measured disease-related
dimerization of mutant SOD1. Previous studies showed
that mutant SOD1 forms Triton X-100 insoluble and so-
dium dodecyl sulfate (SDS)-resistant dimer in the spinal
cord of transgenic mice at symptomatic phase whose ac-
cumulation is inversely correlated with proteasome and
chaperone activities [8,19]. We found that the dimerized
SOD1 (approximately 40 kDa) in the spinal cord of a
SOD1G93A-L/PrP-Sirt1 mouse was less than that of a
littermate SOD1G93A-L mouse (Figure 5C). Since SDS-
resistant SOD1 dimer was not detected in a presymp-
tomatic SOD1G93A-L mouse (60 days of age) (Figure 5C,
left panel), HSP70i induced through the SIRT1/HSF1
pathway might reduce the accumulation of the toxic
SOD1 dimers after the onset of the symptom. These
findings suggest that the SIRT1/HSF1/HSP70i pathway
contributes to the reduction of toxic misfolded and/oraberrantly dimerized species of SOD1, which accumulate
in the late phase of the disease.Discussion
In this study, we established a line of transgenic mice
that chronically overexpress SIRT1 in the brain and
spinal cord. As expected, overexpression of SIRT1 gave
partial rescue effect on SOD1G93A mice. Supplementa-
tion of SIRT1 in the CNS slowed the disease progression
and extended the lifespan of SOD1G93A-L mice with a
reduction of misfolded/aggregated SOD1 presumably
through the activation of the HSF1/HSP70i pathway.
Previous reports from other groups showed that SIRT1
overexpression causes deficits in reference memory in
the novel object recognition test [20], voluntary move-
ment in the open field test, and motor coordination in
the rotating rod test [21]. In contrast, we detected no
significant neurological or behavioral differences be-
tween PrP-Sirt1 mice and their non-transgenic litter-
mates with a few minor exceptions (Table 1, Additional
file 1: Figure S3-S17). The discrepancy might be due to
the transgene constructions, genomic position effects,
and epigenetic factors that affect the levels and spatio-
temporal patterns of expression. Our PrP-Sirt1 mice
with minimal neurological deficits are suitable for testing
the effects of SIRT1 supplementation on various models
of neurological disorders. In fact, their remarkable resist-
ance against cerebral hypoperfusion has been demon-
strated with a bilateral carotid artery stenosis model [22].
The beneficial role of SIRT1 has been demonstrated in
various neurodegenerative disease models. Neuroprotec-
tive effects of SIRT1 have been reported in Huntington’s
disease [23,24], Parkinson’s disease [25], Alzheimer’s dis-
ease [26,27], and spinal and bulbar muscular atrophy
[28]. In this study, we demonstrated that SIRT1 overex-
pression has partial protective effects on a mouse ALS
model. Previous studies showed that resveratrol, an acti-
vator of SIRT1, extended the lifespan of SOD1G93A mice
[15,16]. However, given the pleiotropic effects of resvera-
trol through other target proteins, our results provide
Figure 2 Expression of endogenous SIRT1 and the major heat shock proteins in the spinal cord of SOD1G93A, SOD1G37R or SIRT1 transgenic
mice. (A) Endogenous SIRT1 and HSP70i were upregulated in high copy SOD1G93A mouse (SOD1G93A-H) spinal cord. A representative immunoblot image
for SIRT1 and HSP70i in the lumbar spinal cord of SOD1G93A-H, SOD1G93A-H and PrP-Sirt1 double transgenic (SOD1G93A-H/PrP-Sirt1), or non-transgenic (nTg)
mice at designated age. Each lane contained 30 μg total protein and the similar results were obtained from three independent experiments. (B) Endogenous
SIRT1 was upregulated in SOD1G37R mouse spinal cord. A representative immunoblot image for SIRT1 in the lumbar spinal cord of SOD1G37R, PrP-Sirt1, or
nTg mice at designated age. Each lane contained 20 μg total protein and the similar results were obtained from three independent experiments. (C) HSP70i
was modestly induced in SOD1G37R mouse spinal cord. Representative immunoblot images for HSP70i, HSP90, and HSP110 in the same lumber spinal cord
homogenates as in (B). Each lane contained 30 μg total protein and the similar results were obtained from three independent experiments.
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the alleviation of neurodegeneration in the ALS model.
Our findings suggest that the beneficial effects of SIRT1
depend at least in part on the HSF1/HSP70i pathway. This
is consistent with a previous study demonstrating that
HSF1 overexpression is partially protective against SOD1-
mediated toxicity through the induction of HSP70i and
αB-crystallin [29]. On the other hand, it should be noted
that this study does not exclude possible involvement of
other downstream effectors of SIRT1, such as PGC-1α , or
p53, in the neuroprotective effects.HSP70i reduces Triton X-100-insoluble SOD1 species
(Figure 5C) [8] and exogenously delivered HSP70i ex-
tends the lifespan of SOD1G93A mice [30]. Although it
is unknown whether the mutant SOD1 proteins are
refolded, degraded or both in each case, these data sug-
gest the reduction of toxic SOD1 species contributes to
the amelioration of SOD1-linked ALS model mice by
inducing HSP70i. Since endogenous chaperone system
was not sufficiently activated in SOD1-linked ALS model
mice (Figure 2C) [9], supplementation of HSPs would be
a promising means to cope with the proteotoxicity of
Figure 3 Effects of SIRT1 overexpression on the lifespan and onset of non-transgenic, and high and low copy SOD1G93A transgenic
mice. (A and B) Survival (A) and the onset of the symptom, determined by weight reduction (B) of SOD1G93A-L (n = 19) and SOD1G93A-L/PrP-Sirt1
(n = 16) mouse cohort plotted over time. (C and D) Survival (C) and the onset of the symptom (D) of SOD1G93A-H (n = 21) and SOD1G93A-H/PrP-Sirt1
(n = 15) mouse cohort plotted over time. The data were analyzed by log-rank test and the average onset and survival time are shown with SD.
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pression does not ameliorate the symptom and pathology
of SOD1G93A, SOD1G37R, and SOD1G85R transgenic mouse
lines [31]. We speculate that the differences come from the
severity of the models. As we demonstrated, SIRT1 overex-
pression was effective for the rescue of SOD1G93A-L but
not of SOD1G93A-H (Figure 3), whose levels of HSP70i
in the end stage were comparable (Additional file 1:
Figure S1). These findings suggest that the refolding cap-
acity of HSP70i against the toxicity of mutant SOD1 is
limited, especially in the presence of excess amounts of
misfolded proteins by overexpression of transgene.
We have previously demonstrated that E6-associated
protein (E6-AP), a dual function steroid hormone receptor
coactivator and ubiquitin-protein ligase, is involved in
SOD1 aggresome degradation and suppresses mutant
SOD1-mediated toxicity [32]. Interestingly, E6-AP ubiqui-
tinates the misfolded proteins that are bound to HSC70
[33], and co-expression of E6-AP and HSC70 gives more
potent neuroprotection [32]. It is also known that C-
terminus of HSP70-interacting protein (CHIP) is involved
in misfolded protein degradation through the ubiquitin-
proteasome system [34,35]. These observations suggestthat the chaperone system and the ubiquitin-proteasome
system are closely coordinated to cope with the proteo-
toxic stress. Proteasomal function is inhibited by mutant
SOD1 [19,36] and the expression of HSP70i has peaked
out at the end stage of the disease even in the case of
SOD1G93A-L (Additional file 1: Figure S1). These data sug-
gest that accumulation of proteotoxic species caused by
proteasomal dysfunction could readily excess the capacity
of the chaperone system. Therefore, coordinated activa-
tion of the chaperone system and protein degradation sys-
tems that include the ubiquitin-proteasome system and
the autophagy system is critical to cope with the proteo-
toxicity of mutant SOD1 or other causative proteins of
neurodegenerative diseases.
Conclusion
The genetic supplementation of SIRT1 can ameliorate a
mutant SOD1-linked ALS mouse model partly through
the positive regulation of the HSF1/HSP70i chaperone
system. Future studies shall include identifying other
downstream effectors and testing potential benefits of
pharmacological enhancement of the deacetylation activ-
ity of SIRT1 after the onset of the symptom.
Figure 4 Effects of SIRT1 overexpression on the disease duration of non-transgenic, and high and low copy SOD1G93A transgenic mice.
(A) Definition of the early and late phases of the disease. (B-D) Comparison of the total (B), early (C), and late (D) phases of the disease duration.
SIRT1 overexpression extended the total disease duration in the SOD1G93A-L mice by extending the late phase. The data were analyzed by
one-way ANOVA following post-hoc t-tests. *, p < 0.05; **, p < 0.01.
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Generation of SIRT1 transgenic mice and crossbreeding
with mutant SOD1 mice
To generate a line of transgenic mice that chronically over-
express SIRT1 in the central nervous system, we con-
structed a transcription unit by inserting the coding region
of the mouse Sirt1 cDNA into the MoPrP (mouse prion
gene promoter)-polyA cassette (Figure 1A) [37]. We in-
jected linearized MoPrP-Sirt1 transcription unit with a
genetic marker (mouse αA-crystallin promoter-driven en-
hanced green fluorescent protein (EGFP)) into C57BL/6 J
mouse oocytes and obtained a founder that transmitted the
transgene in Mendelian manner. The genotyping was done
by polymerase chain reaction for an artificial sequence near
the MoPrP-Sirt1 junction. The transgenic line is to be de-
posited to RIKEN Bioresource Center. Sirt1 transgenic and
non-transgenic control mice for behavioral analyses were
bred as littermates. Transgenic mouse lines expressing hu-
man SOD1 gene with ALS-linked mutations, SOD1G93A-H
[B6.Cg-Tg(SOD1*G93A)1Gur/J] or loxSOD1G37R [B6.Cg-
Tg(SOD1-G37R) 1Dwc/J] were previously described
[17,18]. SOD1G93A-L was generated by a spontaneousdrop of the copy number of the SOD1G93A-H line, and
has been maintained in our laboratory for several
generations.
Animals and experimental design
All animal procedures were conducted in accordance with
the guidelines of the Animal Use and Care Committees of
Kyoto University, National Institute for Physiological Sci-
ence, Nagoya University, and RIKEN. All comparisons
were made between littermates to minimize confounding
effects of different genetic background and environment.
All behavioral tests were conducted at 5–9 months of age
as described previously [38,39]. Mice were group housed
(4 mice per cage) in a specific pathogen-free room kept at
23 ± 2°C with a 12 h light/dark cycle (lights on at 7 a.m.)
with access to food and water. For survival experiments,
SOD1G93A mice were always compared with their litter-
mates with PrP-Sirt1 gene. Times of disease onset, early
phase, and end stage were determined respectively as the
time when mice had started losing the maximum body
weight, when denervation-induced muscle atrophy had
produced a 10% loss of maximal weight, and when
Figure 5 Effects of SIRT1 overexpression on the induction of HSP70i in the spinal cord of SOD1G93A-L/PrP-Sirt1 transgenic mice.
(A) HSF1 was significantly deacetylated in 5-month-old PrP-Sirt1 mouse spinal cord. Acetylated HSF1 was detected with anti-acetylated lysine
antibody after the immunoprecipitation with anti-HSF1 antibody. (B) HSP70i was significantly induced in the PrP-Sirt1 mouse spinal cord.
(C) Sirt1 overexpression reduced the insoluble SOD1 species in the end-stage SOD1G93A mouse spinal cord. Triton X-100 insoluble and
SDS-resistant SOD1G93A dimer (arrowhead, ~40 kDa) was detected by immunoblotting (left panel). The relative densitometric values were shown
as mean ± SEM (right panel). SIRT1 overexpression significantly suppressed aggregation and insolubilization of SOD1G93A. Each lane in A, C, and
D contained 15 μg of total protein and the similar results were obtained from three independent experiments.
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onds, an endpoint commonly used for mutant SOD1 ex-
pressing mice which is compliant with the requirements
of the Animal Use and Care Committee. Disease progres-
sion was defined by the duration between the onset and
disease end-stage. Statistical analysis of survival time and
disease duration was performed with a log-rank test and
one-way ANOVA following post-hoc t-tests, respectively.
Analyses were carried out by using GraphPad Prism
(GraphPad Software, La Jolla, CA).
Genotyping of mice
Mice harboring PrP-Sirt1 transgene were identified by
PCR using following primers; 5′-CAAGAGGTTGT
TAATGAAGC-3′ and 5′-TTTCCTGTTGCCTTCAAT
CAGCTATCG-3′.Mice harboring SOD1G93A or SOD1G37R transgene were
identified by PCR using following primers; the mouse SOD1
gene fragment (850 bp) was amplified by mSOD-A primer:
5′-GTTACATATAGGGGTTTACTTCATAATCTG-3′ and
h/mSOD-C primer: 5′-CAGCAGTCACATTGCCCARG
TCTCCAACATG-3′, and human SOD1 gene fragment




We used the following commercially available antibodies:
anti-SIRT1 from EMD Millipore Corp. (Billerica, MA,
USA), anti-β-actin from Sigma-Aldrich Co. LLC. (St. Louis,
MO, USA), anti-acetylated lysine from Cell Signaling Tech-
nology Inc. (Danvers, MA, USA), anti-HSF1, anti-HSP70i
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http://www.molecularbrain.com/content/7/1/62and anti-HSP90 from Enzo Life Sciences Inc. (Farmingdale,
NY, USA). Rabbit anti-human SOD1 antibody was raised
against a recombinant human SOD1 peptide (24–36) and
purified with protein A [40].
Immunoblotting
Tissues were homogenized in TNE lysis buffer [50 mM
Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM ethylenediamine-
tetraacetic acid (EDTA), 1% Triton-X 100, protease inhi-
bitor cocktail (Roche, Basel, Switzerland)] with Dounce
homogenizer. The lysates were centrifuged at 15,000 × g for
10 min at 4°C and the supernatants were collected. For the
analyses of insoluble SOD1, the pellets were re-solubilized
in the equivalent volume of TNE lysis buffer supplemented
with 2% SDS and benzonase (Roche). After minutes of in-
cubation at room temperature, the lysates were sonicated
and centrifuged at 15,000 × g for 10 min. The supernatants
were collected as insoluble fractions. All the protein con-
tent was measured by micro BCA assay kit (Thermo Fisher
Scientific Inc., Waltham, MA, USA) and equal amounts of
total proteins were analyzed by immunoblotting. Densito-
metric analysis was performed after the chemiluminescence
detection by using an image analyzer LAS-4000mini (Fuji
film, Tokyo, Japan) with the equipped software.
Immunoprecipitation
For the detection of HSF1 deacetylation, we slightly modi-
fied the previously reported procedure [14]. In brief, lumbar
spinal cords were homogenized in radioimmunoprecipita-
tion (RIPA) buffer [50 mM Tris–HCl (pH 8.0), 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS]
supplemented with 1 mM EDTA, 2 mM nicotinamide
and 1 mM trichostatin A (all from Sigma) with Dounce
homogenizer. The lysates were centrifuged at 15,000 × g
for 10 min at 4°C. Anti-HSF1 antibody (1:100) was added
to the supernatant and incubated for over-night at 4°C
with gentle agitation. Protein G sepharose (GE Healthcare,
Waukesha, WI, USA; 15 μl each) was added and incubated
for further 1.5 h. The beads were washed four times with
phosphate buffered saline. The proteins were eluted with
2 × SDS loading buffer and heating at 95°C for 3 min. Dea-
cetylated and total HSF1 were detected on the same poly-
vinylidene difluoride membrane with Restore western blot
stripping buffer (Thermo).
Additional file
Additional file 1: Additional experimental procedures and figures.
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